Boehringer Ingelheim and Zealand Pharma plan to expand their three-year-old collaboration to develop new peptide medicines, with Boehringer agreeing to license one of Zealand’s preclinical therapeutic peptide projects. The companies are already working to develop and commercialize a new glucagon/GLP-1 dual-acting peptide therapeutic designed to treat patients with type 2 diabetes and/or obesity … more

Separately, Boehringer Ingelheim has established a research alliance with the University of Toronto through the Toronto Recombinant Antibody Centre, together with Toronto-based University Health Network and the Mount Sinai Hospital there to characterize new therapeutic targets in the field of ubiquitin biology. Alterations of the ubiquitin system are linked to many common diseases such as cancer, diabetes, inflammation, and central nervous system disorders … more